Inclusion of Ipragliflozin into the Vital and Essential Drugs List: Budget Impact Analysis

Medical Technologies Assessment and Choice (Медицинские технологии Оценка и выбор) ◽

10.31556/2219-0678.2019.38.4.055-061 ◽

2019 ◽

pp. 55-61

Author(s):

Tatiana Valerevna Boyarskaya ◽

Elena Vladimirovna Derkach

Keyword(s):

Impact Analysis ◽

Budget Impact ◽

Target Population ◽

Budget Impact Analysis ◽

Essential Drugs ◽

Type 2 Dm ◽

Number Of Patients ◽

Average Maximum ◽

The Cost

The sodium-glucose co-transporter type 2 inhibitors (SGLT2i) used in the treatment of type 2 diabetes mellitus (DM) do not only affect the blood glucose level, but also help to reduce body weight and blood pressure. Recently ipragliflozin, the new drug from the SGLT2i group has appeared on the Russian market. The aim of this study was to analyze the budget impact of including ipragliflozin into the vital and essential drugs (VED) list for treatment of type 2 DM in adults. Material and methods. Budget impact analysis was performed in a mathematical model. The modeling period was 5 years. The target population included adult patients with type 2 DM eligible for glucose-lowering therapy with SGLT2i. The number of patients during the modeling period was calculated based on the information about SGLT2i public procurement and the data from the Federal Register of DM (FRDM). The cost of ipragliflozin was calculated on the basis of the price planned for state registration if the drugis included into the VED list (2.118 rubles for 30 tablets, 50 mg each); costs of dapagliflozin and empagliflozin were equal to the registered maximum selling prices plus VAT and the weighted average maximum wholesale allowance in the Russian Federation. The sensitivity analysis was performed to the variability of prices and target population size. Results. The estimated number of patients treated with SGLT2i was 14.052 in the 1-st year and 47.392 in the 5-th year. The calculated difference in the cost of SGLT2i over 5 years between the current and the expected practice (if ipragliflozin is included into the VED list) was –3.02 million rubles (cost reduction by 0.06%). For the first year, costs decreased by 0.1 million rubles, or 0.02%. Conclusion. The inclusion of ipragliflozin into the VED list leads to a reduction in costs within the budget of the State guarantee program for free provision of medical care to citizens.

Download Full-text

PDB16 THE COST-UTILITY AND BUDGET IMPACT ANALYSIS OF SITAGLIPTIN (JANUVIA®) IN TYPE 2 DIABETES IN POLAND

Value in Health ◽

10.1016/s1098-3015(10)66663-6 ◽

2008 ◽

Vol 11 (6) ◽

pp. A500

Author(s):

J Walczak ◽

I Malczak ◽

A Panasiuk ◽

D Pawlik ◽

K Lasota ◽

...

Keyword(s):

Type 2 Diabetes ◽

Impact Analysis ◽

Budget Impact ◽

Cost Utility ◽

Budget Impact Analysis ◽

The Cost

Download Full-text

AB0634 BUDGET IMPACT ANALYSIS OF BIOLOGICAL THERAPY COMPARED TO CONVENTIONAL SPONDYLOARTHRITIS TREATMENT, IN A FOURTH LEVEL HOSPITAL IN BOGOTA COLOMBIA

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2020-eular.5143 ◽

2020 ◽

Vol 79 (Suppl 1) ◽

pp. 1612.2-1613

Author(s):

J. M. Bello-Gualtero ◽

O. J. Calixto ◽

G. Salguedo ◽

Y. M. Chamorro-Melo ◽

C. A. Camargo Rodríguez ◽

...

Keyword(s):

Ankylosing Spondylitis ◽

Annual Cost ◽

Impact Analysis ◽

Budget Impact ◽

Biological Therapy ◽

Biologic Therapy ◽

Disease Diagnosis ◽

Budget Impact Analysis ◽

Military Hospital ◽

Number Of Patients

Background:Spondyloarthritis refers to a family of diseases, of which ankylosing spondylitis and non-radiographic axial spondyloarthritis are responsible for axial impairment. Previously, the only treatment available were NSAIDs, which control activity and stop radiological progression, but at the expense of increased adverse effects, such as cardiovascular risk, dyspepsia and chronic renal failure. For the past 2 decades, biological therapy has been available, which means an increase in care costs.Objectives:The objective of this study is to perform a budget impact analysis of biologic therapy.Methods:To do a budget impact analysis from the perspective of the payer, comparing biological therapy with coventional therapy for the treatment of spondyloarthritis. Demographic characterization of the population attended at the Central Military Hospital. Time horizon from 2012 to 2018, taking the activity count according to the hospital’s billing and the prices of the activities of the state body SISMED. Exchange rates at the end of 2018.Results:The patients attended were 117, mostly men (63, 25%), average age 46, 4 years (SD 13), with disease diagnosis time of 9, 8 years (SD 9, 6). In the budget impact analysis, it is observed that 25% of patients were on DMARDs therapy, 22% with NSAIDs and 96% with biologic therapy. The average year/patient cost with NSAIDs alone would be EUR 381, with DMARDs only EUR 9,318 and, if only biological therapy was used, EUR 423. Within the total number of patients, the average annual cost, including the possibility of combining these drugs, amounted to EUR 5,403Conclusion:Including biological therapy in the care of patients with spondyloarthritis can increase up to 24 times the annual cost per patient. This increase is not only due to higher market value, it also relates to the need for more medical procedures and diagnostic follow-up tests.References:[1]Strömbeck, et al. Cost of Illness from the Public Payers’ Perspective in Patients with Ankylosing Spondylitis in Rheumatological Care. J Rheumatol 2010;37;2348-2355.Disclosure of Interests:None declared

Download Full-text

PCN99 THE COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF RITUXIMAB(HANLIKANG) FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN CHINA

Value in Health ◽

10.1016/j.jval.2019.09.296 ◽

2019 ◽

Vol 22 ◽

pp. S455

Author(s):

M.M. Zhao ◽

Y. Xiang ◽

W. Juying ◽

S.H. Jia ◽

B.B. Chen ◽

...

Keyword(s):

Cost Effectiveness ◽

B Cell ◽

Impact Analysis ◽

Budget Impact ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

Budget Impact Analysis ◽

Large B Cell Lymphoma ◽

The Cost ◽

Large B Cell

Download Full-text

Budget impact analysis of the use of rituximab in the treatment of rheumatoid arthritis in Italy

Farmeconomia Health economics and therapeutic pathways ◽

10.7175/fe.v10i1.160 ◽

2009 ◽

Vol 10 (1) ◽

pp. 19-31 ◽

Cited By ~ 1

Author(s):

Maurizio Benucci ◽

Sergio Iannazzo ◽

Luciano Sabadini

Keyword(s):

Rheumatoid Arthritis ◽

Impact Analysis ◽

Budget Impact ◽

Unit Cost ◽

Budget Impact Analysis ◽

Second Line ◽

Number Of Patients ◽

Biologic Dmard ◽

Third Line ◽

The Impact

Objective: a Budget Impact analysis was performed to evaluate cost implications for the Italian National Health Service (NHS) of the introduction of rituximab (RTX) in the treatment of rheumatoid arthritis (RA). Methods: RA patients eligible to treatment with a second-line biologic DMARD (Disease Modifying Antirheumatic Drugs) were identified and quantified and available strategies for their management were explored. Costs associated with the different alternatives were estimated, and the impact on the NHS budget was estimated using a cohort simulation based on a Markov chain with a time horizon of 5 years and 1-year cycles. Seven alternative strategies were analyzed, each of them starting after the failure of a first anti-TNFα: 1) the use of a second and a third anti-TNFα; 2) the use of a second anti-TNFα followed by RTX; 3) the use of a second anti-TNFα followed by abatacept (ABAT); 4) the use of RTX as a second biological line, followed by an anti-TNFα; 5) the use of ABAT as a second biological line, followed by an anti-TNFα; 6) the use of RTX as a second biological line, followed by ABAT; 7) the use of ABAT as a second biological line, followed by RTX. Only direct medical costs were considered: drug acquisition, administration, incidental premedication and monitoring exams. Results: Italian patients eligible to second biological line therapies (RA patients refractory or intolerant to at least one anti-TNFα therapy) were estimated in about 650 per year. The adoption of RTX as a second line therapy produced a substantial saving in total costs (-33% at the fifth year) with respect to the strategy with RTX as third line and the one with only anti-TNFα (the last two resulting substantially cost-equivalent). The number of patients in active treatment (biologic DMARD) per unit cost resulted of about 8.1 patient-years/100,000 € with the strategy based only on anti-TNFα and increased of 10% with RTX as a third line. The strategy of RTX as a second line provided a further 41% increase (with respect to RTX as a third line). Conclusions: the introduction of RTX in the treatment of Italian RA patients represents a valuable new therapeutic option for this population especially if anticipated after a first anti-TNFα failure; it can also induce a reduction in health resources consumption for the NHS.

Download Full-text